
LENZ Therapeutics, Inc. - Common Stock
Share · US52635N1037 · LENZ (XNAS)
29,00 USD
13.06.2025 20:00
Current Prices from LENZ Therapeutics, Inc. - Common Stock
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() NASDAQ |
LENZ
|
USD
|
13.06.2025 20:00
|
29,00 USD
| 29,58 USD
-1,96 %
|
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
-1,96 % | -12,97 % | -1,36 % | 17,89 % | -5,78 % | 55,00 % | -66,88 % |
Company Profile for LENZ Therapeutics, Inc. - Common Stock Share
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Company Data
Name LENZ Therapeutics, Inc. - Common Stock
Company LENZ Therapeutics, Inc.
Symbol LENZ
Website
https://www.lenz-tx.com
Primary Exchange
NASDAQ

ISIN US52635N1037
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Evert B. Schimmelpennink
Market Capitalization 670 Mio
Country United States of America
Currency USD
Employees 0,0 T
Address 445 Marine View Avenue, 92014 Del Mar
IPO Date 2024-03-22
Dividends from 'LENZ Therapeutics, Inc. - Common Stock'
Ex-Date | Dividend per Share |
---|---|
22.03.2024 | 0,15 USD |
ID Changes
Date | From | To |
---|---|---|
22.03.2024 | GRPH | LENZ |
Ticker Symbols
Name | Symbol |
---|---|
NASDAQ | LENZ |
More Shares
Investors who LENZ Therapeutics, Inc. - Common Stock hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.